Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin
Volume: 13 Issue: 2
Author(s): Saad Hussain Syed, Sucheta Gosavi, Waseem Shami, Marco Bustamante, Zul Farah, Muhammad Teleb, Aamer Abbas, Sarmad Said and Debabrata Mukherjee
Affiliation:
Keywords: Anti-hyperglycemic agents, dipeptidyl peptidase-4 inhibitors, fasting plasma glucose, sulphonylureas, sodium glucose co-transporter 2 inhibitors, SGLT2, type 1 diabetes mellitus, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first drug approved in this group in 2013 and subsequently dapagliflozin was approved in January 2014 and empagliflozin was approved in August 2014. Preclinical studies have demonstrated safety, tolerability, and efficacy in terms of glycemic control and HbA1c level in type 2 diabetes mellitus (T2DM) patients in comparison to other anti-diabetic drugs. The U.S. Food and Drug Administration (FDA) recently released a warning that some of the patients who used SGLT2 inhibitors developed diabetic ketoacidosis (DKA). Empagliflozin has showed safety in type 2 diabetics with renal impairment. Each of these medications can be used as a single treatment or in combination with other anti-diabetic medications.
Export Options
About this article
Cite this article as:
Syed Hussain Saad, Gosavi Sucheta, Shami Waseem, Bustamante Marco, Farah Zul, Teleb Muhammad, Abbas Aamer, Said Sarmad and Mukherjee Debabrata, A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin , Cardiovascular & Hematological Agents in Medicinal Chemistry 2015; 13 (2) . https://dx.doi.org/10.2174/1871525714666151106121215
DOI https://dx.doi.org/10.2174/1871525714666151106121215 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Diagnosis and New Approaches in the Therapy of Gestational Diabetes Mellitus
Current Diabetes Reviews The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus
Current Diabetes Reviews Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Signaling Pathways Involved in Physiopathology of Pancreatic β -Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Herbal Drugs for Diabetic Treatment: An Updated Review of Patents
Recent Patents on Anti-Infective Drug Discovery Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature
Current Diabetes Reviews Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Clozapine Safety, 35 Years Later
Current Drug Safety Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Model-Based Insulin and Nutrition Administration for Tight Glycaemic Control in Critical Care
Current Drug Delivery Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Erythropoietin and Oxidative Stress
Current Neurovascular Research Local Cerebral Blood Flow is Preserved in Sepsis
Current Neurovascular Research Structure Activity Relationship Studies of Gymnemic Acid Analogues for Antidiabetic Activity Targeting PPARγ
Current Computer-Aided Drug Design Diabetes Exacerbates Nanoparticles Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews The IGF-I Signaling Pathway
Current Pharmaceutical Design Prevalence of Diabetes Ketoacidosis Rises and Still No Strict Treatment Adherence
Current Diabetes Reviews